Jump to content

Fluoroproscaline

Add links
From Wikipedia, the free encyclopedia

Fluoroproscaline
Clinical data
Other namesFP; 3-Fluoroproscaline; 3-FP; 4-(3-Fluoropropoxy)-3,5-dimethoxyphenethylamine
Routes of
administration		Oral[1][2]
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Duration of action3–5 hours[1][2]
Identifiers
  • 2-[4-(3-fluoropropoxy)-3,5-dimethoxyphenyl]ethanamine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC13H20FNO3
Molar mass257.305 g·mol−1
3D model (JSmol)
  • COC1=CC(=CC(=C1OCCCF)OC)CCN
  • InChI=1S/C13H20FNO3/c1-16-11-8-10(4-6-15)9-12(17-2)13(11)18-7-3-5-14/h8-9H,3-7,15H2,1-2H3
  • Key:FMAGEKSBHIYXPF-UHFFFAOYSA-N

Fluoroproscaline (FP), also known as 4-(3-fluoropropoxy)-3,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline.[1][2] It is a fluorinated derivative of proscaline.[1][2][3] The drug has a dose range of 60 to 150 mg and a duration of 3 to 5 hours.[1][2] It is less potent than proscaline but more potent than mescaline and is much shorter-acting than proscaline or mescaline.[1][2] The receptor interactions of fluoroproscaline have been studied.[4][1][2] It is a low-affinity and low-potency agonist of the serotonin 5-HT2A receptor.[4][1][2] The chemical synthesis of fluoroproscaline has been described.[3] The drug was first described in the scientific literature by Daniel Trachsel in 2002.[2][1][3] The pharmacology of fluoroproscaline was studied in greater detail in 2021.[4] It is not a controlled substance in Canada as of 2025.[5]

See also

[edit]

References

[edit]
  1. ^ a b c d e f g h i Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. pp. 706, 712, 716–717, 736–737. ISBN 978-3-03788-700-4. OCLC 858805226.
  2. ^ a b c d e f g h i Trachsel D (2012). "Fluorine in psychedelic phenethylamines". Drug Testing and Analysis. 4 (7–8): 577–590. doi:10.1002/dta.413. PMID 22374819. A fluorinated analog of proscaline (79) [3] was also investigated.[86] At the cloned [3 H]ketanserin-labelled serotonin h5-HT2A receptor fluoroproscaline (80: Ki= 8792nM) showed only low affinity and in humans, fluoroproscaline (80: 60–150 mg, 3–5 h) was distinctly less potent and of shorter duration than proscaline (79: 30–60 mg, 8–12 h). Similarly, limited trials suggest that trifluoroproscaline (81: 66 mg or more) might be less potent as well. The preparation of difluoroisoproscaline (82), a fluoro analog of the psychedelic derivative isoproscaline (83),[3] has been achieved.[5]
  3. ^ a b c Trachsel D (2002). "Synthese von neuen (Phenylalkyl)aminen zur Untersuchung von Struktur-Aktivitätsbeziehungen, Mitteilung 1, Mescalin Derivate". Helvetica Chimica Acta. 85 (9): 3019–3026. doi:10.1002/1522-2675(200209)85:9<3019::AID-HLCA3019>3.0.CO;2-4.
  4. ^ a b c Kolaczynska KE, Luethi D, Trachsel D, Hoener MC, Liechti ME (2021). "Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines". Frontiers in Pharmacology. 12 794254. doi:10.3389/fphar.2021.794254. PMC 8865417. PMID 35222010.
  5. ^ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
[edit]
Stub icon

This hallucinogen-related article is a stub. You can help Wikipedia by adding missing information.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Fluoroproscaline&oldid=1333819222"